`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`————————————————
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`————————————————
`MYLAN PHARMACEUTICALS INC. and
`AMNEAL PHARMACEUTICALS LLC,
`
`Petitioners,
`
`v.
`
`YEDA RESEARCH & DEVELOPMENT CO. LTD.
`
`Patent Owner.
`————————————————
`Case IPR2015-00644
`Patent No. 8,399,413
`————————————————
`
`SIXTH UPDATED LIST OF PETITIONERS’ EXHIBITS
`
`Pursuant to 37 C.F.R. § 42.63(e), Petitioners submit the following current
`
`exhibit list.
`
`Exhibit No.
`
`1001
`
`1002
`
`1003
`
`1003A
`
`1003B
`
`1004
`
`Description
`U.S. Patent No. 8,399,413, Low Frequency Glatiramer Acetate
`Therapy (filed Aug. 19, 2010) (issued May 19, 2013)
`
`File History for U.S. Patent No. 8,399,413
`
`[Corrected] Declaration of Stephen J. Peroutka, M.D., Ph.D.
`
`Curriculum Vitae of Stephen J. Peroutka, M.D., Ph.D.
`
`Materials Reviewed by Stephen J. Peroutka, M.D., Ph.D.
`
`Expert Declaration of Ari Green, M.D.
`
`1004A
`
`Curriculum Vitae of Ari Green, M.D.
`
`
`
`1
`
`
`
`Exhibit No.
`1004B
`
`Description
`Materials Reviewed by Ari Green, M.D.
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`1005
`
`1006
`
`Irit Pinchasi: International Publication No. WO 2007/081975
`(published July 19, 2007)
`
`J.A. Cohen et al., Randomized, double-blind, dose-comparison
`study of glatiramer acetate in relapsing-remitting MS, 68:12
`NEUROLOGY, 939-44 (2007)
`
`1007
`
`Affidavit of Marlene S. Bobka dated December 9, 2014
`
`1007A
`
`John J. Jessop, Review and Evaluation of Pharmacology
`Toxicology Data Original NDA Review (1996) (the 1996 FDA
`SBOA) (attached as Exhibit A to Exh. 1007)
`
`1008
`
`1009
`
`1010
`
`1011
`
`Shlomo Flechter et al., Copolymer 1 (Glatiramer Acetate) in
`Relapsing Forms of Multiple Sclerosis: Open Multicenter Study
`of Alternate-Day Administration. 25:1 CLINICAL
`NEUROPHARMACOLOGY, 11-15 (2002) (Flechter 2002A)
`
`Zeev Meiner et al., Copolymer 1 in relapsing-remitting multiple
`sclerosis: a multi-centre trial, in FRONTIERS IN MULTIPLE
`SCLEROSIS: CLINICAL RESEARCH AND THERAPY (Oded
`Abramsky and Haim Ovadia, eds., 1997)
`
`Omar Khan et al., Randomized, prospective, rater-blinded,
`four-year, pilot study to compare the effect of daily versus
`every-other-day glatiramer acetate 20 mg subcutaneous
`injections in relapsing-remitting multiple sclerosis, 14
`MULTIPLE SCLEROSIS, S296 (2008)
`
`Christina Caon et al., Randomized, Prospective, Rater-Blinded,
`Four Year Pilot Study to Compare the Effect of Daily Versus
`Every Other Day Glatiramer Acetate 20 mg Subcutaneous
`Injections in RRMS, 72:11(3) NEUROLOGY, A317 (2009)
`
`2
`
`
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`Shlomo Flechter et al., Comparison of glatiramer acetate
`(Copaxone) and interferon β-1b (Betaferon) in multiple
`sclerosis patients: an open-label 2-year follow up, 197
`JOURNAL OF THE NEUROLOGICAL SCIENCES, 51-55 (2002).
`(“Flechter 2002B”)
`
`James R Miller, The importance of early diagnosis of multiple
`sclerosis, 10(3) (Suppl. S-b) J. MANAG. CARE PHARM., S4-11
`(2004)
`
`M.B. Bornstein, Multiple Sclerosis: Trial of a Synthetic
`Polypeptide, 11:3 ANNALS OF NEUROLOGY, 317-19 (1982)
`
`M.B. Bornstein et al., Clinical Trial of Copolymer I in Multiple
`Sclerosis, 436 ANNALS NEW YORK ACADEMY OF SCIENCES,
`366-372 (1984)
`
`M.B. Bornstein et al., A Pilot Trial of COP 1 in Exacerbating-
`Remitting Multiple Sclerosis, 317:7 THE NEW ENGLAND
`JOURNAL OF MEDICINE, 408-14 (1987)
`
`FDA, GUIDELINE FOR INDUSTRY: Dose-Response
`Information to Support Drug Registration (1994)
`
`K.P. Johnson, et al., Copolymer 1 reduces relapse rate and
`improves disability in relapsing-remitting multiple sclerosis, 43
`NEUROLOGY, 1268-1276 (1995)
`
`Exhibit No.
`
`1012
`
`1013
`
`1014
`
`1015
`
`1016
`
`1017
`
`1018
`
`1019
`
`Affidavit of Marlene S. Bobka dated January 5, 2015
`
`1019A
`
`1020
`
`1996 FDA Meeting Agenda minutes from the Peripheral and
`Central Nervous System Drug Advisory Committee (dated
`September 19, 1996) (Exhibit A to Exhibit 1019)
`Ruth Arnon, The development of Cop 1(Copaxone®), an
`innovative drug for the treatment of multiple sclerosis: personal
`reflections, 50 IMMUNOLOGY LETTERS 1-15 (1996)
`
`3
`
`
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`Leslie Z. Benet et al., Pharmacokinetics: The Dynamics of
`Drug Absorption, Distribution, and Elimination, in THE
`PHARMACOLOGICAL BASIS OF THERAPEUTICS, 3 (Alfred
`Goodman Gilman ed. 1996)
`
`E. Lobel, et al., Copolymer-1, 21(2) DRUGS OF THE FUTURE,
`131-134 (1996)
`
`Haines et al., Linkage of the MHC to familial multiple sclerosis
`suggests genetic heterogeneity. The multiple sclerosis genetics
`group, HUM. MOL. GENET. 7:1229-34 (Aug 1998)
`
`U.S. Patent No. 6,342,476, Copolymer-1 Improvements in
`Compositions of Copolymers (2002).
`
`Y. Ge et al., Glatiramer acetate (Copaxone) treatment in
`relapsing-remitting MS: Quantitative MR assessment, 54
`NEUROLOGY, 813-17 (2000)
`
`Giancarlo Comi et al., European/Canadian multicenter, double-
`blind, randomized, placebo-controlled study of the effects of
`glatiramer acetate on magnetic resonance imaging-measured
`disease activity and burden in patients with relapsing multiple
`sclerosis: European/Canadian Glatiramer Acetate Study
`Group, 49:3 ANN. NEUROL., 290-97 (2001)
`
`Boissel and Nony, Using pharmacokinetic-pharmacodynamic
`relationships to predict the effect of poor compliance, CLIN.
`PHARMACOL. 41:1-6 (2002)
`
`Exhibit No.
`
`1021
`
`1022
`
`1023
`
`1024
`
`1025
`
`1026
`
`1027
`
`1028
`
`McBride, INT’L J. MS CARE 4:85 (2002)
`
`1029
`
`1030
`
`Dene Simpson, Adis Drug Evaluation Glatiramer Acetate – A
`Review of its use in Relapsing-Remitting Multiple Sclerosis,
`16:12 CNS DRUGS, 825-50, 834 (2002)
`
`Catherine M. Edgar, et al., Lipoatrophy in Patients with
`Multiple Sclerosis on Glatiramer Acetate, 31 CAN. J. NEUROL.
`SCI., 58-63 (2004)
`
`4
`
`
`
`Exhibit No.
`
`1031
`
`1032
`
`1033
`
`1034
`
`1035
`
`1036
`
`1037
`
`1038
`
`1039
`
`1040
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`Rich et al., Stepped-care approach to treating MS: A managed
`care treatment algorithm, J. MANAGED CARE PHARM. 10:S26-
`S32 (June 2004)
`
`Stuart, Clinical management of multiple sclerosis: The
`treatment paradigm and issues of patient management, J.
`MANAGED CARE PHARMACY 10:S19-S25 (June 2004)
`
`Rohit Bakshi et al., Imaging of Multiple Sclerosis: Role in
`Neurotherapeutics, 2(2) NEURORX, 277–303 (2005)
`
`Paul Beringer et al., Clinical Pharmacokinetics and
`Pharmacodynamics, in REMINGTON: THE SCIENCE AND
`PRACTICE OF PHARMACY, 1191-1205, 1197, 1201 (Paul
`Beringer ed., 2005)
`
`Michael Franklin et al., Drug Absorption, Action, and
`Disposition, in REMINGTON: THE SCIENCE AND PRACTICE OF
`PHARMACY, 1142-1170, 1167 (Paul Beringer ed., 2005)
`
`James Rasmussen: International Patent Publication No. WO
`2005/120542 A2 (published December 22, 2005)
`
`Devonshire et al., The Global Adherence Project – A
`multicentre observational study on adherence to disease-
`modifying therapies in patients suffering from relapsing-
`remitting multiple sclerosis, MULTIPLE SCLEROSIS 12:S1 (P316)
`(2006)
`
`C.C. Ford et al., A prospective open-label study of glatiramer
`acetate: over a decade of continuous use in multiple sclerosis
`patients, 12 MULTIPLE SCLEROSIS, 309-320 (2006)
`
`Frohman, Multiple Sclerosis – The Plaque and its Pathogenesis,
`NEW ENGLAND J. MED. 354:942-55 (2006)
`
`J.J. Kragt et al., How similar are commonly combined criteria
`for EDSS progression in multiple sclerosis?, 12(6) MULTIPLE
`SCLEROSIS782-786 (2006)
`
`5
`
`
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`Peter J. Manso et al., Life cycle management of ageing
`pharmaceutical assets, 3:7 PHARMACEUTICAL LAW INSIGHT,
`(2006)
`
`Soares et al., Localized panniculitis secondary to subcutaneous
`glatiramer acetate injections for the treatment of multiple
`sclerosis: a clinicopathologic and immunohistochemical study,
`J. AM. ACAD. DERM. 55:968-74 (2006)
`
`Klauer and Zettl, Compliance, adherence and the treatment of
`multiple sclerosis, J. NEUROL. 255 [Suppl. 6]:87-92 (2008)
`
`Pelidou et al., Multiple sclerosis presented as clinically isolated
`syndrome: the need for early diagnosis and treatment, THER.
`CLIN. RISK MANAGEMENT 4:627-30 (June 2008)
`
`Tjalf Ziemssen et al., Effects of glatiramer acetate on fatigue
`and days of absence from work in first-time treated relapsing-
`remitting multiple sclerosis, 6 HEALTH AND QUALITY OF LIFE
`OUTCOMES 67 (2008)
`
`Teva Provides Update on Forte Trial Jerusalem, Israel
`(July 7, 2008)
`Copaxone® U.S. Product Label (2001)
`Betaseron® U.S. Product Label (2003)
`Rebif® U.S. Product Label (2003)
`Avonex® Product Label (2006)
`Tysabri® Product Label (2008)
`Copaxone® U.S. Product Label (Feb. 2009)
`Extavia® Product Label (2009)
`
`Exhibit No.
`
`1041
`
`1042
`
`1043
`
`1044
`
`1045
`
`1046
`
`1047
`
`1048
`
`1049
`
`1050
`
`1051
`
`1052
`
`1053
`
`6
`
`
`
`Exhibit No.
`
`1054
`
`1055
`
`1056
`
`1057
`
`1058
`
`1059
`
`1060
`
`1061
`
`1062
`
`1065
`
`1066
`
`1067
`
`1068
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`Jacobs et al., Intramuscular interferon beta-1a therapy initiated
`during a first demyelinating event in multiple sclerosis, NEW
`ENGL. J. MED 343:898-904 (2000) (“Jacobs”)
`
`Stedman’s Medical Dictionary for Health Professionals (2008)
`
`U.S. Patent Publication No. 2009/0149541A1 (filed Nov. 26,
`2008)
`
`Concepts in clinical pharmacokinetics, in INTRODUCTION TO
`PHARMACOKINETICS AND PHARMACODYNAMICS, Tozer and
`Rowland eds (Lippincott Williams & Wilkins 2006)
`
`M. Tintore et al., Baseline MRI predicts future attacks and
`disability in clinically isolated syndromes, 67 NEUROLOGY 968-
`972, (2006).
`
`FDA GUIDANCE FOR INDUSTRY - POPULATION
`PHARMACOKINETICS (1999)
`
`REBIF® Product Label (June 2005)
`
`http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.
`cfm?Appl_No=020622&Product_No=003&table1=OB_Rx
`(accessed February 5, 2015)
`
`https://scamparoo.wordpress.com/2008/04/11/ms-therapies-
`copaxone/ (dated April 11, 2008 (accessed February 5, 2015))
`
`October 22, 2015 Deposition of Dr. Ari Green
`
`October 29, 2015 Deposition of Dr. Stephen Peroutka
`
`Petitioners’ Notice of Deposition of Dr. Edward J. Fox
`
`O. Khan, et al., Glatiramer acetate 20mg subcutaneous twice -
`weekly versus daily injections: results of a pilot, prospective,
`randomised, and rater-blinded clinical and MRI 2-year study in
`relapsing-remitting multiple sclerosis, MULTIPLE SCLEROSIS
`2009; 15:S151-S269, S249-S250 (2009)
`
`7
`
`
`
`Exhibit No.
`
`1069
`
`1070
`
`1071
`
`1072
`
`1073
`
`1074
`
`1075
`
`1076
`
`1077
`
`1078
`
`1079
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`G. Pardo, et al., Impact of an oral antihistamine on local
`injection site reactions with glatiramer acetate, MULTIPLE
`SCLEROSIS, 2007; 13:S7-S2753, S134 (2007)
`
`S. Bains, et al., Glatiramer acetate: successful desensitazation
`for treatment of multiple sclerosis, ANNALS OF ALLERGY,
`ASTHMA & IMMUNOLOGY, 2010;104:321-325.
`
`E. Fisher, et al., Gray Matter Atrophy in Multiple Sclerosis: A
`Longitudinal Study, ANNALS OF NEUROLOGY, 2008;64:255-265
`
`Fourth Declaration of Edward J. Fox, M.D., Ph.D., In re
`Copaxone 40 mg Consolidated Cases, Civil Action No. 1:14-
`cv-001171, ECF No. 155 (D. Del.)
`
`G. Anderson, et al., Tolerability and safety of novel half
`milliliter formulation of glatiramer acetate for subcutaneous
`injection: an open-label, multicenter, randomized comparative
`study, JOURNAL OF NEUROLOGY (2010) 257:1917-1923
`
`G. Shaw, Exorbitant Drug Costs May Price Out Patients, THE
`WASHINGTON DIPLOMAT (April 27, 2011).
`
`Letter, Mitrokostas to White dated January 19, 2016
`
`Stipulated Protective Order in In re Copaxone 40 mg
`Consolidated Cases, No. 1:14-cv-01171 (GMS) (entered by
`minute entry on May 27, 2015)
`
`Jazz Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC et
`al., No. 2:13-cv-00391, Order January 22, 2016
`
`Transcript of January 21, 2016 Teleconference
`
`T. Ziemssen, et al., A 2-year observational study of patients
`with relapsing-remitting multiple sclerosis converting to
`glatiramer acetate from other disease-modifying therapies: the
`COPTIMIZE trial, JOURNAL OF NEUROLOGY (2014) 261:2101–
`2111
`
`8
`
`
`
`Exhibit No.
`
`1080
`
`1081
`
`1082
`
`1083
`
`1084
`
`1085
`
`1086
`
`1087
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`T. Ziemssen, et al., Sub-analysis of geographical variations
`inthe 2-year observational COPTIMIZE trial of patients with
`relapsing–remitting multiple sclerosis converting to glatiramer
`acetate, BMC NEUROLOGY (2015) 15:189
`
`T. Ziemssen, et al., QualiCOP: An Open-Label, Prospective,
`Observational Study of Glatiramer Acetate in Patients with
`Relapsing-Remitting Multiple Sclerosis
`
`N. Kleiner, et al., Immunological Response to Glatiramer
`Acetate in MS Patients after Different Pretreatments – The
`CopImmunoNet Study, P06.178, A554 NEUROLOGY 74, Suppl 2
`(March 2, 2010)
`
`Teva News Release, New Study Demonstrated Significant
`Reduction in Annualized Relapse Rate and Halting of Disability
`Progression in MS Patients Switching to Copaxone® (April 14,
`2011)
`
`R. Aharoni, et al., Glatiramer acetate-specific T cells in the
`brain express T helper 2/3 cytokines and brain-derived
`neurotrophic factor in situ, PNAS 100(24):14157-14162
`(November 25, 2003)
`
`Expert Declaration of Ari Green, M.D. in Support of
`Petitioner’s Reply to Patent Owner’s Response
`
`Teva’s Shared Solutions® How to Prepare for Your Injection,
`http://www.copaxone.com/injection-assistance/preparing-your-
`injection.html (last visited Mar. 7, 2016)
`
`Louise Gagnon, Every-Other-Day Dosing of Glatiramer
`Acetate Reduces Adverse Reactions with Comparable Efficacy
`to Daily Dosing: Presented at WCTRMS, PEERVIEW PRESS,
`Sept. 21, 2008, http://www.peerviewpress.com/every-other-
`day-dosing-glatiramer-acetate-reduces-adverse-reactions-
`comparable-efficacy-daily-dosing-presented-wctrms (last
`visited Mar. 8, 2016)
`
`9
`
`
`
`Exhibit No.
`
`1088
`
`1089
`
`1090
`
`1091
`
`1092
`
`1093
`
`1094
`
`1095
`
`1096
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`J. Wolinsky, Glatiramer acetate for the treatment of multiple
`sclerosis, EXPERT OPINION ON PHARMACOTHERAPY, 5(4):875–
`891 (2004) (“Wolinsky 2004”)
`
`O. Khan et al., Glatiramer acetate 20mg subcutaneous twice-
`weekly versus daily injections: results of a pilot, prospective,
`randomised, and rater-blinded clinical and MRI 2-year study in
`relapsing-remitting multiple sclerosis, MULTIPLE SCLEROSIS,
`15:S151–S269 (2009) (“Khan 2009”)
`
`M.S. Weber et al., Mechanism of Action of Glatiramer Acetate
`in Treatment of Multiple Sclerosis, NEUROTHERAPEUTICS,
`4(4):647–653 (2007) (“Weber”)
`
`W.F. Hickey et al., T-Lymphocyte Entry Into the Central
`Nervous System, J. OF NEUROSCIENCE RESEARCH, 28(2):254–
`260 (1991) (“Hickey 1991B”)
`
`T.M. Stewart et al., Injectable Multiple Sclerosis medications:
`A Patient Survey of Factors Associated with Injection-Site
`Reactions, INT’L J. MS CARE, 14(1):46–53 (2012)
`
`U.S. Dep’t Health & Human Servs., Common Terminology
`Criteria for Adverse Events (CTCAE) (Version 4.03 June 14,
`2010)
`
`B. Singer et al., Comparative injection-site pain and tolerability
`of subcutaneous serum-free formulation of interferonβ-1a
`versus subcutaneous interferonβ-1b: results of the randomized,
`multicenter, Phase IIIb REFORMS study, BMC NEUROLOGY,
`12:154 (2012)
`
`L. McEwan et al., Best Practices in Skin Care for the Multiple
`Sclerosis Patient Receiving Injectable Therapies, INT’L J. MS
`CARE, 12:177–189 (2010)
`
`R. Bermel et al., The measurement and clinical relevance of
`brain atrophy in multiple sclerosis, LANCET NEUROL.,
`5(2):158–70 (2006)
`
`10
`
`
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`E. Fisher et al., Gray Matter Atrophy in Multiple Sclerosis: A
`Longitudinal Study, ANN. NEUROL., 4:255–265 (2008)
`
`Lauren LeBano, Gray Matter Atrophy May Serve as an
`Effective Outcome measure for MS Clinical Trials, NEUROL.
`REVIEWS, 20(2):8 (2012)
`
`Exhibit No.
`
`1097
`
`1098
`
`1099
`
`Declaration of Prof. Joel W. Hay
`
`1100
`
`1101
`
`1102
`
`1103
`
`1104
`
`1105
`
`Xinke Zhang et al., Cost Effectiveness of Fingolimod,
`Teriflunomide, Dimethyl Fumarate and Intramuscular
`Interferon-β1a in Relapsing-Remitting Multiple Sclerosis, 29(1)
`CNS DRUGS 71 (2015)
`
`Xinke Zhang & Joel W. Hay, Cost-effectiveness of Fingolimod,
`Teriflunomide, Dimethyl Fumarate and Intramuscular
`Interferon Beta-1a in Relapsing-remitting Multiple Sclerosis,
`Poster, Monday Morning, PND20, ISPOR 19th Annual
`International Conference, May 2014, Montreal, Quebec,
`Canada
`
`Xinke Zhang & Joel W. Hay, Cost-effectiveness of Fingolimod,
`Teriflunomide, Dimethyl Fumarate and Intramuscular
`Interferon Beta-1a in Relapsing-remitting Multiple Sclerosis,
`American Society for Health Economics 5th Biennial
`Conference, June 2014, Los Angeles, CA
`
`Matthew Herper, Inside The Secret World of Drug Company
`Rebates, FORBES PHARMA & HEALTHCARE (May 10, 2012),
`http://www.forbes.com/sites/matthewherper/2012/05/10/why-
`astrazeneca-gives-insurers-60-discounts-on-nexiums-list-
`price/#155191dd4fd6
`
`Thomas Reinke, MS Drug Going Generic Without Making
`Waves, MANAGED CARE (June 2015), http://bit.ly/1KcyXdE
`
`Carly Helfand, Why is Novartis’ Copaxone copy lagging? It's
`all about coverage, analyst explains, FIERCE PHARMA (Sept. 11,
`2015), http://bit.ly/1ia8BNM
`
`11
`
`
`
`Exhibit No.
`
`1106
`
`1107
`
`1108
`
`1109
`
`1110
`
`1111
`
`1112
`
`1113
`
`1114
`
`1115
`
`1116
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`3-Times-A-Week Copaxone® 40 MG, TEVA,
`https://www.copaxone.com/about-copaxone/copaxone-40-mg
`
`Biogen Press Release, Biogen 2015 Revenues Increase 11% to
`$10.8 Billion (Jan. 27, 2016), BIOGEN.COM,
`http://bit.ly/1OXIl1x
`
`A to Z of MS Alemtuzumab (Lemtrada), MULTIPLE SCLEROSIS
`TRUST, http://bit.ly/1YnIfHQ
`
`R. Osborne, Buzz around Campath proof-of-concept trial in
`MS, 27(1) NATURE BIOTECHNOLOGY 6 (2009)
`
`J. A. Cohen et al., Alemtuzumab versus interferon beta 1a as
`first-line treatment for patients with relapsing-remitting
`multiple sclerosis: a randomized controlled phase 3 trial, 380
`LANCET, 3801819 (2012)
`
`IMS INSTITUTE FOR HEALTH INFORMATICS, MEDICINE USE AND
`SHIFTING COSTS OF HEALTHCARE, Chart Notes (April 2014)
`
`IMS INSTITUTE FOR HEALTH INFORMATICS, DECLINING
`MEDICINE USE AND COSTS: FOR BETTER OR WORSE?, Chart
`Notes (May 2013)
`
`Valeant Pharms. Int’l, Inc., Transcript of June 17, 2014 Investor
`Presentation, http://1.usa.gov/21PTRZK
`
`Brian Orelli, Momenta Slowed (Temporarily), THE MOTLEY
`FOOL (Nov. 7, 2015), http://bit.ly/1YiNNmS
`
`Carly Helfand, The top 10 best-selling multiple sclerosis drugs
`of 2013, FIERCEPHARMA (Sept. 9, 2014), http://bit.ly/1UKrlDd
`
`Tracy Staton, Sanofi tags newly OK’d MS drug Lemtrada at
`$158K, ready to tout head-to-head Rebif data,
`FIERCEPHARMAMARKETING (Nov. 17, 2014),
`http://bit.ly/1QDkTIZ
`
`12
`
`
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`Kim Frick et al., Serono to sell Amgen multiple sclerosis drug
`[Novantrone] in U.S., FIRSTWORD PHARMA (Nov. 13, 2002),
`http://bit.ly/1QXqhpR
`
`Christopher Luzzio & B. Mark Keegan, Multiple Sclerosis
`Medication, MEDSCAPE REFERENCE (Nov. 24, 2014),
`http://emedicine.medscape.com/article/1146199-medication#1
`
`MOMENTUMMAGAZINEONLINE.COM, 10 DISEASE-MODIFYING
`TREATMENTS, Nov. 2013, available at http://bit.ly/1eVa0jT.
`
`IMS Health, U.S. Pharmaceutical Market: Trends Issues &
`Outlook (Sept. 15, 2013)
`
`Jesse David & Marion B. Stewart, Commercial Success:
`Economic Principles Applied to Patent Litigation, in ECONOMIC
`DAMAGES IN INTELLECTUAL PROPERTY: A HANDS-ON GUIDE TO
`LITIGATION 159 (Daniel Slottje ed., John Wiley & Sons, Inc.
`2006)
`
`Angela Maas, New Copaxone Formulation Could Help Teva
`Retain Market Share, AIS HEALTH, Feb. 19, 2014,
`http://bit.ly/21POaLm
`
`MISSOURI DEP’T OF SOC. SERVS., SPECIALTY MAXIMUM
`ALLOWABLE COST (MAC) (Mar. 1, 2016),
`http://dss.mo.gov/mhd/cs/pharmacy/pdf/macspec.pdf
`
`Gina Shaw, Glatopa Is Strong Out of the Gate, SPECIALTY
`PHARMACY CONTINUUM (July 22, 2015), http://bit.ly/1p8U4Gb
`
`DAVID RISINGER ET AL., MORGAN STANLEY ANALYST REPORT:
`TEVA PHARMACEUTICAL INDUSTRIES LTD. (Mar. 14, 2014)
`
`Financial Support, Copaxone, TEVA,
`https://www.copaxone.com/shared-solutions/copaxone-savings-
`and-benefits (accessed Dec. 28, 2015)
`
`Exhibit No.
`
`1117
`
`1118
`
`1119
`
`1120
`
`1121
`
`1122
`
`1123
`
`1124
`
`1125
`
`1126
`
`13
`
`
`
`Exhibit No.
`
`1127
`
`1128
`
`1129
`
`1130
`
`1131
`
`1132
`
`1133
`
`1134
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`Copaxone, TEVA, https://www.copaxone.com (accessed Jan. 8,
`2016)
`
`Emerging Therapies Collaborative, Organization Disclosures,
`MS COALITION, http://www.ms-
`coalition.org/emergingtherapies/disclosures/organization-
`disclosures (accessed Mar. 6, 2016)
`
`Alisa Woods, The Costs of Multiple Sclerosis Treatment,
`EVERYDAY HEALTH (Feb. 22, 2016),
`http://www.everydayhealth.com/multiple-
`sclerosis/treatment/costs-of-ms-treatment/
`
`Geeta Anand, Through Charities, Drug Makers Help People –
`and Themselves, WALL ST. J. (Dec. 1, 2005),
`http://www.wsj.com/articles/SB113339802749110822
`
`Malcolm Gladwell, High Prices: How to think about
`prescription drugs, NEW YORKER (Oct. 25, 2004),
`http://www.newyorker.com/magazine/2004/10/25/high-prices
`(accessed Feb. 28, 2016)
`
`Ernst R. Berndt et al., An Analysis of the Diffusion of New
`Antidepressants: Variety, Quality, and Marketing Efforts, 5(1)
`J. OF MENTAL HEALTH POL’Y AND ECONS. 3 (2002)
`
`Ernst R. Berndt et al., Information, marketing, and pricing in
`the U.S. antiulcer drug market, 85(2) AM. ECON. REV. 100
`(1995)
`
`FDA approves new MS treatment regimen developed at Wayne
`State University by Dr. Omar Khan, DIVISION OF RESEARCH -
`RESEARCH@WAYNE,
`https://research.wayne.edu/rwnews/article.php?id=1319 (last
`visited Mar. 8, 2016)
`
`1135
`
`Pinchasi prosecution history
`
`14
`
`
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Description
`Order Construing the Terms of U.S. Patent Nos. 8,232,250,
`8,399,413, 8,969,302, and 9,155,776, In Re Copaxone 40 mg
`Consolidated Cases, No. 14-1171-GMS (consolidated) (D. Del.
`Mar. 7, 2016), ECF No. 214
`
`Stipulation and [Proposed] Order Concerning Claim
`Construction Dispute, In Re Copaxone 40 mg Consolidated
`Cases, No. 14-1171-GMS (consolidated) (D. Del. Feb. 12,
`2016), ECF No. 194
`
`Transcript of Trial Testimony, Teva Pharms. USA, Inc. v.
`Sandoz, Inc., No. 1:09-cv-08824 (S.D.N.Y. Sept. 7, 2011), ECF
`No. 205
`
`Ampyra Prescribing Information, ACORDA THERAPEUTICS (Dec.
`2014)
`
`Public Version of the Deposition of Dr. Jerry S. Wolinsky taken
`in In re Copaxone 40 mg Consolidated Cases, No. 14-1171 (D.
`Del. Feb. 15, 2016)
`
`April 4, 2016 Deposition of Dr. Joel Hay
`
`April 6, 2016 Deposition of Dr. Ari Green
`
`Letter, Anstaett to Bennett dated February 26, 2016 (redacted)
`
`Letter, Bennett to Anstaett dated March 7, 2016 (redacted)
`
`Email, Anstaett to Bennett dated April 1, 2016 (redacted)
`
`Exhibit No.
`
`1136
`
`1137
`
`1138
`
`1139
`
`1140
`
`1141
`
`1142
`
`1143
`
`1144
`
`1145
`
`
`
`
`
`15
`
`
`
`
`
`
`
`/Brandon M. White/
`Brandon M. White
`Reg. No. 52,354
`
`PERKINS COIE LLP
`700 13th Street, NW, Suite 600
`Washington, D.C. 20005
`Telephone: (202) 654-6204
`Facsimile: (202) 654-6211
`Email: bmwhite@perkinscoie.com
`
`Attorney for Mylan Pharmaceuticals Inc.
`
`Case IPR2015-00644
`Patent No. 8,399,413
`
`
`Dated: April 22, 2016
`
`
`
`
`
`16
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that the foregoing Sixth Updated List of
`
`Petitioners’ Exhibits was served electronically via email as follows:
`
`Patent Owners:
`
`
`Elizabeth Holland
`Goodwin Procter LLP
`eholland@goodwinprocter.com
`
`William James
`Goodwin Procter LLP
`wjames@goodwinprocter.com
`
`Eleanor Yost
`Goodwin Procter LLP
`eyost@goodwinprocter.com
`
`Nicholas Mitrokostas
`Goodwin Procter LLP
`nmitrokostas@goodwinprocter.com
`
`Daryl Wiesen
`Goodwin Procter LLP
`dwiesen@goodwinprocter.com
`
`John Bennett
`Goodwin Procter LLP
`jbennett@goodwinprocter.com
`
`
`Petitioner Amneal Pharmaceuticals, LLC:
`
`
`Vincent L. Capuano
`Duane Morris LLC
`VCapuano@duanemorris.com
`
`Christopher S. Kroon
`Duane Morris LLC
`CSKroon@duanemorris.com
`
`
`Dated: April 22, 2016
`
`
`
`
`
`
`
`
`
`/Brandon M. White/
`Brandon M. White
`
`Attorneys for Mylan Pharmaceuticals Inc.